Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 9032502, 7 pages
https://doi.org/10.1155/2017/9032502
Research Article

MiR-219-5p Inhibits the Growth and Metastasis of Malignant Melanoma by Targeting BCL-2

1Department of Dermatology, The First Clinical Medicine School, Hubei University of Chinese Medicine, Wuhan, China
2Department of Dermatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China
3Department of Dermatology, Hubei Provincial Academy of Traditional Chinese Medicine, Wuhan, China
4Department of Dermatology, Mongolian Medicine Hospital, Bortala Mongol Autonomous Prefecture, China

Correspondence should be addressed to Jianwen Long; moc.mcthbh@newnaijgnol

Received 24 May 2017; Accepted 11 July 2017; Published 13 August 2017

Academic Editor: Vasiliki Galani

Copyright © 2017 Jianwen Long et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Achkar and A. A. Tarhini, “The use of immunotherapy in the treatment of melanoma,” Journal of hematology oncology, vol. 10, no. 1, p. 88, 2017. View at Publisher · View at Google Scholar
  2. A. A. Tarhini, “Immunotherapy of melanoma,” Current Molecular Pharmacology, vol. 9, no. 3, pp. 196–207, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Davar, A. A. Tarhini, and J. M. Kirkwood, “Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach,” Clinics in Dermatology, vol. 31, no. 3, pp. 237–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Olszanski, “Current and future roles of targeted therapy and immunotherapy in advanced melanoma,” Journal of Managed Care Pharmacy, vol. 20, no. 4, pp. 346–356, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. K. S. Hoek, “Melanoma progression, gene expression and DNA microarrays,” G Ital Dermatol Venereol, vol. 144, no. 1, pp. 39–49, 2009. View at Publisher · View at Google Scholar
  6. E. Hulstaert, L. Brochez, P. Volders, J. Vandesompele, and P. Mestdagh, “Long non-coding RNAs in cutaneous melanoma: clinical perspectives,” Oncotarget, 2017. View at Publisher · View at Google Scholar
  7. Y. Tutar, “miRNA and cancer; computational and experimental approaches,” Current Pharmaceutical Biotechnology, vol. 15, no. 5, p. 429, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, “microRNAs as oncogenes and tumor suppressors,” Developmental Biology, vol. 302, no. 1, pp. 1–12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Wang, “Predicting cancer-related MiRNAs using expression profiles in tumor tissue,” Current Pharmaceutical Biotechnology, vol. 15, no. 5, pp. 438–444, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Lynam-Lennon, S. G. Maher, and J. V. Reynolds, “The roles of microRNA in cancer and apoptosis,” Biological Reviews, vol. 84, no. 1, pp. 55–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. N. Aftab, M. E. Dinger, and R. J. Perera, “The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma,” Archives of Biochemistry and Biophysics, vol. 563, pp. 60–70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Cheng, R. Deng, P. Zhang et al., “MIR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4,” Oncology Reports, vol. 34, no. 4, pp. 1923–1932, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. K.-B. Song, W.-J. Liu, and S.-S. Jia, “MiR-219 inhibits the growth and metastasis of TSCC cells by targeting PRKCI,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 9, pp. 2957–2965, 2014. View at Google Scholar · View at Scopus
  14. N. McGranahan and C. Swanton, “Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future,” Cell, vol. 168, no. 4, pp. 613–628, 2017. View at Publisher · View at Google Scholar
  15. M. Klingenberg, A. Matsuda, S. Diederichs, and T. Patel, “Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets,” Journal of Hepatology, 2017. View at Publisher · View at Google Scholar
  16. H. Sha, D. Wang, D. Chen et al., “MiR-138: A promising therapeutic target for cancer,” Tumor Biology, vol. 39, no. 4, Article ID 101042831769757, 2017. View at Publisher · View at Google Scholar
  17. C. Li, J. Dong, Z. Han, and K. Zhang, “MicroRNA-219-5p Represses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Targeting the LRH-1/Wnt/β-Catenin Signaling Pathway,” Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, vol. 25, no. 4, pp. 617–627, 2017. View at Publisher · View at Google Scholar
  18. S. W. Lowe, E. Cepero, and G. Evan, “Intrinsic tumour suppression,” Nature, vol. 432, no. 7015, pp. 307–315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Choi, K. Choi, E. N. Benveniste et al., “Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2,” Cancer Research, vol. 65, no. 13, pp. 5554–5560, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. H. Kang and C. P. Reynolds, “BcI-2 Inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy,” Clinical Cancer Research, vol. 15, no. 4, pp. 1126–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus